S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in

NASDAQ:VBLT - Vascular Biogenics Stock Price, Forecast & News

$1.43
+0.02 (+1.42 %)
(As of 01/20/2020 04:00 PM ET)
Today's Range
$1.39
Now: $1.43
$1.45
50-Day Range
$1.10
MA: $1.24
$1.44
52-Week Range
$0.93
Now: $1.43
$1.90
Volume130,960 shs
Average Volume116,352 shs
Market Capitalization$51.31 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.29
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBLT
Previous SymbolNASDAQ:VBLX
CUSIPN/A
Phone972-8993-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$580,000.00
Book Value$1.48 per share

Profitability

Net Income$-20,460,000.00
Net Margins-3,050.43%

Miscellaneous

Employees39
Market Cap$51.31 million
Next Earnings Date3/26/2020 (Estimated)
OptionableOptionable

Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter.


Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd (NASDAQ:VBLT) released its quarterly earnings data on Thursday, November, 14th. The biopharmaceutical company reported ($0.14) EPS for the quarter, hitting analysts' consensus estimates of ($0.14). The biopharmaceutical company earned $0.08 million during the quarter, compared to the consensus estimate of $0.24 million. Vascular Biogenics had a negative net margin of 3,050.43% and a negative return on equity of 37.19%. View Vascular Biogenics' Earnings History.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Vascular Biogenics.

What price target have analysts set for VBLT?

5 brokerages have issued 12-month target prices for Vascular Biogenics' stock. Their forecasts range from $2.00 to $3.25. On average, they anticipate Vascular Biogenics' share price to reach $2.75 in the next year. This suggests a possible upside of 92.3% from the stock's current price. View Analyst Price Targets for Vascular Biogenics.

What is the consensus analysts' recommendation for Vascular Biogenics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vascular Biogenics.

What are Wall Street analysts saying about Vascular Biogenics stock?

Here are some recent quotes from research analysts about Vascular Biogenics stock:
  • 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (1/15/2020)
  • 2. Chardan Capital analysts commented, "We understand the colon cancer trial will be a single- arm open label design, providing the possibility of an early look at efficacy signals, with data anticipated in 2020. We expect more details on these programs as the GBM and colon cancer trials begin." (5/16/2019)

Has Vascular Biogenics been receiving favorable news coverage?

News coverage about VBLT stock has trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vascular Biogenics earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Vascular Biogenics.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 43,300 shares, a drop of 25.3% from the December 15th total of 58,000 shares. Based on an average daily trading volume, of 64,200 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.2% of the shares of the stock are sold short. View Vascular Biogenics' Current Options Chain.

Who are some of Vascular Biogenics' key competitors?

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include Alibaba Group (BABA), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), AEterna Zentaris (AEZS), Synergy Pharmaceuticals (SGYP), vTv Therapeutics (VTVT), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Opko Health (OPK) and Sangamo Therapeutics (SGMO).

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the folowing people:
  • Prof. Dror Harats, CEO & Director (Age 62)
  • Mr. Amos Ron, CFO & Company Sec. (Age 64)
  • Dr. Erez Feige, VP of Bus. Operations (Age 45)
  • Dr. Eyal Breitbart, VP of Research & Operations (Age 52)
  • Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 65)

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.43.

How big of a company is Vascular Biogenics?

Vascular Biogenics has a market capitalization of $51.31 million and generates $580,000.00 in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Vascular Biogenics employs 39 workers across the globe.View Additional Information About Vascular Biogenics.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is http://www.vblrx.com/.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]


MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  248 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  524
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel